769 related articles for article (PubMed ID: 23810002)
1. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
2. Sex hormone receptors in breast cancer.
D'Abreo N; Hindenburg AA
Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
5. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
6. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
9. Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective.
Jordan VC; Knudson AG
Oncology (Williston Park); 2006 May; 20(6):553-62; discussion 567-8, 573, 577. PubMed ID: 16773843
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications.
Biggar RJ
Clin Cancer Res; 2012 Apr; 18(8):2133-7. PubMed ID: 22368159
[TBL] [Abstract][Full Text] [Related]
11. SERMs: meeting the promise of multifunctional medicines.
Jordan VC
J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
[TBL] [Abstract][Full Text] [Related]
12. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
[TBL] [Abstract][Full Text] [Related]
13. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
14. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
15. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Provenzano A; Kurian S; Abraham J
Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
[TBL] [Abstract][Full Text] [Related]
16. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
17. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.
Jordan VC; Lewis JS; Osipo C; Cheng D
Breast; 2005 Dec; 14(6):624-30. PubMed ID: 16202599
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
19. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
20. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Cleator SJ; Ahamed E; Coombes RC; Palmieri C
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]